NCT05926531

Brief Summary

Insomnia is a disorder characterized by both nocturnal and daytime symptoms. The main symptoms are unsatisfactory sleep quality or duration, accompanied by difficulty falling asleep before bedtime, frequent or prolonged awakenings, or an inability to fall back asleep after waking in the early morning. Our previous investigation has confirmed that during the period of home isolation of the epidemic, the community people suffered from acute insomnia induced by the epidemic. In order to comprehensively, efficiently and scientifically respond to major public health emergencies such as the COVID-19 epidemic and its long-term impact, it is necessary to carry out in-depth and systematic research on insomnia related issues of medical staff under the COVID-19 epidemic. In summary, insomnia is a widespread problem among medical staff during the epidemic, which greatly reduces the work efficiency of medical staff and damages their physical and mental health. Without timely and effective early identification and effective intervention, allowing the disease to continue to develop will bring a series of concurrent diseases, threaten the lives of medical staff and bring a series of negative social effects. At the same time, the diagnosis and intervention of large-scale acute insomnia for medical staff under the epidemic face some scenario limitations, and it is necessary to consider the spread of the virus to reduce direct contact. Especially for some medical staff in isolation, it is more difficult to implement face-to-face evaluation, diagnosis and treatment. Under the COVID-19 pandemic, there are two main contradictions in the acute insomnia of medical staff. The first is the lack of a diagnostic cloud platform based on artificial intelligence for large-scale acute insomnia. The second is the lack of an effective remote intervention for acute insomnia suitable for the epidemic scenario. Based on the results and deficiencies of the previous research, this project intends to further study and improve in three aspects. First, a large-scale and more accurate artificial intelligence-based automatic screening and diagnosis model research was carried out in combination with CPC equipment for acute insomnia screening of medical staff under the epidemic situation. The second is to use epidemic insomnia acute insomnia CPR to intervene the acute insomnia and other psychiatric symptoms of medical staff on a large scale and verify its effectiveness through follow-up. Third, for the epidemic scenario, further build an intelligent screening and remote intervention system platform for acute insomnia for the majority of medical staff, and continue to provide an assessment, intervention and consultation platform for medical staff under the epidemic. Therefore, in order to comprehensively cope with the increase in the incidence of acute insomnia among medical staff under the COVID-19 epidemic and its resulting disease, social and economic burden, we should pay attention to the mental health of medical staff in the first-level key susceptible population, and improve the response experience of major public health emergencies in the future. This project aims to establish a portable and efficient artificial intelligent-based diagnosis cloud platform method and remote intervention system for medical staff with acute insomnia under the epidemic situation, which is suitable for large-scale development. Based on the data collected by portable devices and electronic scales, a risk assessment model for acute insomnia and other psychiatric symptoms of medical staff in the epidemic situation is constructed, and effective intervention is carried out on this basis. To promote the establishment of a comprehensive prevention and treatment system for insomnia after the epidemic, comprehensively carry out systematic work from multiple perspectives, improve mental health, summarize and form China's experience in dealing with major public emergencies, and promote it internationally, so as to reduce the impact and loss caused by the COVID-19 epidemic on a global scale.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 15, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 29, 2023

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 3, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2024

Completed
Last Updated

July 3, 2023

Status Verified

June 1, 2023

Enrollment Period

1 year

First QC Date

June 29, 2023

Last Update Submit

June 29, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • evaluation of scale

    insomnia severity index (ISI) score, more reduction mean better outcome

    7 days

Secondary Outcomes (1)

  • total sleep time

    7 days

Study Arms (4)

acute insomnia treatment group

EXPERIMENTAL

CBTI and VR intervention for one week

Device: CBTI online programe

acute insomnia control group

NO INTERVENTION

no intervention

chronic insomnia treatment group

EXPERIMENTAL

CBTI and VR intervention for one week

Device: CBTI online programe

chronic insomnia control group

NO INTERVENTION

no intervention

Interventions

20 MIN VR RELAX PROGRAME

Also known as: VR
acute insomnia treatment groupchronic insomnia treatment group

Eligibility Criteria

Age18 Years - 59 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • \) meet the DSM-5 criteria for insomnia;
  • \) Insomnia severity index (ISI) ≥8;
  • \) Sleep Efficiency \< 85%;
  • \) aged 18-59 years;
  • \) can understand and adhere to the study protocol;
  • \) Informed consent can be signed online;
  • \) Have smart terminals (such as smart phones, tablets, computers, etc.) and know how to use wechat and VR devices.

You may not qualify if:

  • \) undiagnosed physical diseases, mental disorders and/or other chronic insomnia;
  • \) received psychotherapy for insomnia in the past month;
  • \) received medication for insomnia prescribed by a medical institution in the past month;
  • \) Frequent time-zone crossing;
  • \) those who are not comfortable with VR equipment;
  • \) those with suicidal ideation;
  • \) severe visual impairment, visual field defect, color blindness and visuospatial neglect; Nervous system disorders (sensory disorders, tremor, involuntary movement, Parkinson's disease, etc.).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanfang Hospital

Guangzhou, Guangdong, China

Location

MeSH Terms

Conditions

Sleep Initiation and Maintenance DisordersDepressionAnxiety Disorders

Condition Hierarchy (Ancestors)

Sleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental DisordersBehavioral SymptomsBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 29, 2023

First Posted

July 3, 2023

Study Start

May 15, 2023

Primary Completion

May 15, 2024

Study Completion

May 15, 2024

Last Updated

July 3, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

Locations